Recent Advances in Management of Epithelial Ovarian Cancer

Abstract

The hallmark of ovarian cancer treatment, over decades, is accurate diagnosis, precise surgical staging, and optimal cytoreduction, followed by chemotherapy in the majority of cases. However, it is distressing to see the development of disease recurrence, resistance, and poor prognosis. Ovarian cancer cells express gene signatures, which pose significant challenges for cancer drug development. The aim of this review is to discuss the recent developments in terms of screening, surgical management, newer chemotherapeutic agents and molecular targeted therapies to improve the overall prognosis of ovarian cancer.

Novel Associations Between Brca1 Variants C.181 T>G (Rs28897672) and Ovarian Cancer Risk in Saudi Females

“…Ovarian cancer is the sixth most common type of cancer in women (1), and is one of the most lethal malignancies in the world (2), often described as a silent killer (3). The lifetime prevalence of ovarian cancer in the developed countries is about 1–2%.…”

“…The lifetime prevalence of ovarian cancer in the developed countries is about 1–2%. The factors associated with the increased risk of ovarian cancer are advancing age, obesity, nulliparity, use of talcum powder, oestrogen and hormone therapy (2). The most important factor in the development of ovarian cancer is a family history of ovarian or breast cancer, although an identifiable genetic predisposition (germline BRCA1/BRCA2 mutation) is found only in 10–15% of the patients (4, 5).…”